Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $849 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $52 | $0 |
| Gross Profit | $0 | $0 | -$52 | $633 |
| % Margin | – | – | – | 74.6% |
| R&D Expenses | $899 | $1,120 | $1,304 | $1,723 |
| G&A Expenses | $1,148 | $1,453 | $1,785 | $1,466 |
| SG&A Expenses | $1,148 | $1,453 | $1,785 | $1,466 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,047 | $2,573 | $3,089 | $3,189 |
| Operating Income | -$2,047 | -$2,573 | -$3,089 | -$3,189 |
| % Margin | – | – | – | -375.6% |
| Other Income/Exp. Net | -$59 | -$330 | $225 | $216 |
| Pre-Tax Income | -$2,106 | -$2,903 | -$2,864 | -$2,973 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,106 | -$2,903 | -$2,864 | -$2,973 |
| % Margin | – | – | – | -350.2% |
| EPS | -0.19 | -0.34 | -0.45 | -0.52 |
| % Growth | 44.1% | 24.4% | 13.5% | – |
| EPS Diluted | -0.19 | -0.34 | -0.45 | -0.52 |
| Weighted Avg Shares Out | 11,008 | 8,620 | 6,342 | 5,708 |
| Weighted Avg Shares Out Dil | 11,008 | 8,620 | 6,342 | 5,708 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $46 | $0 |
| Interest Expense | $0 | $330 | $0 | $66 |
| Depreciation & Amortization | $48 | $51 | $52 | $53 |
| EBITDA | -$1,999 | -$2,522 | -$3,037 | -$3,136 |
| % Margin | – | – | – | -369.4% |